Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China

PURPOSE: Poly (ADP-ribose) polymerase (PARP) inhibitor, is a milestone in treatment of ovarian cancer. However, there is no real world study from China regarding the clinical outcome of the taking PARP inhibitor (PARPi), Olaparib(Lynparza™). The goal of this research is to evaluate the side effects...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Ovarian Res
Hlavní autoři: Ni, Jing, Cheng, Xianzhong, Zhou, Rui, Xu, Xia, Guo, Wenwen, Chen, Xiaoxiang
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6882236/
https://ncbi.nlm.nih.gov/pubmed/31775908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13048-019-0594-1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky